Both DelSite Biotechnologies and ElSohly Laboratories have cooperative R&D agreements with the National Cancer Institute (NCI). Whereas DelSite’s agreement covers the development of a nasal powder vaccine for Human Papillomavirus (HPV), ElSohly’s covers an anticancer drug.
Dr Yawi Ni, senior scientist at DelSite, said “This agreement allows for the GelSite polymer to be used to stabilize and deliver a molecule smaller than we have worked with in the past. We look forward to being involved with this promising molecule and its analogs in the anticancer area. Naturally, it is exciting that our technology is now involved in two key areas of NCI research.”